Site-specific response to nivolumab in renal cell carcinoma

23Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

Background/Aim: Nivolumab monotherapy for advanced/metastatic renal cell carcinoma (RCC) shows a survival benefit. The purpose of this study was to evaluate tumor responses to nivolumab in various metastatic and primary sites in patients with RCC. Patients and Methods: We retrospectively reviewed 68 patients who underwent nivolumab monotherapy after one or more regimens of targeted therapy for advanced/metastatic RCC. The site-specific response was evaluated and progression-free survival was estimated. Results: The site-specific overall response rates (ORRs) were as follows: lung (36%), bone (5%), lymph node (33%), liver (50%), adrenal gland (29%), pancreas (33%), and brain (0%). The ORR of bone metastasis was significantly worse in comparison to lung and liver metastases (p=0.017, 0.008). The site-specific median progression-free survival times were as follows: lung (5.1 months), bone (not reached), lymph node (not reached), and liver (17.5 months). Conclusion: Responses to nivolumab may vary depending on metastasized organs.

Cite

CITATION STYLE

APA

Negishi, T., Furubayashi, N., Nakagawa, T., Nishiyama, N., Kitamura, H., Hori, Y., … Nakamura, M. (2021). Site-specific response to nivolumab in renal cell carcinoma. Anticancer Research, 41(3), 1539–1545. https://doi.org/10.21873/anticanres.14913

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free